inotuzumab,blinatumomab
pfizer,ucb,amgen,astellas
['lymsm', 'inotuzumab', 'blinatumomab']
hyper-cvad plus sequential blinatumomab with or without inotuzumab elicits clinical benefit in ph-negative b-cell all #asco22 #lymsm #oncology 
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.